Skip to content

How to Use CJC-1295: Administration, Reconstitution & Storage (2026)

From Peptidepedia, the trusted peptide wiki.

How to Use / Administration

CJC-1295 is administered via subcutaneous injection, typically into the abdominal fat, thigh, or upper arm.

Injection Process:

  1. Reconstitute the peptide (see below)
  2. Draw the appropriate dose using an insulin syringe (typically 29–31 gauge)
  3. Clean the injection site with an alcohol swab
  4. Pinch the skin and insert the needle at a 45-degree angle
  5. Inject slowly and withdraw the needle
  6. Rotate injection sites to prevent lipodystrophy

For CJC-1295 without DAC, most protocols involve once or twice daily injections, the bedtime dose is considered the most important as it coincides with the body's natural nocturnal GH surge. A morning dose can be added for those seeking additional effect.

For CJC-1295 with DAC, once or twice weekly injections are sufficient due to the extended half-life. Consistency in timing (e.g., every Monday and Thursday) helps maintain stable blood levels.

Reconstitution, Storage & Prep

CJC-1295 is supplied as a lyophilized (freeze-dried) powder that requires reconstitution before use.

Reconstitution Process:

  1. Allow the peptide vial to reach room temperature
  2. Using bacteriostatic water (preferred) or sterile water, slowly inject the diluent down the inside wall of the vial, never directly onto the powder
  3. Gently swirl the vial until the powder is fully dissolved; do not shake vigorously
  4. For a 2 mg vial, adding 2 mL of bacteriostatic water creates a concentration of 1 mg/mL (1000 mcg/mL), making dosing calculations straightforward

Storage Guidelines:

  • Unreconstituted powder: Store in a cool, dry place; refrigeration extends shelf life to 24+ months
  • Reconstituted solution: Must be refrigerated at 2–8°C (36–46°F)
  • With bacteriostatic water: Stable for approximately 4–6 weeks refrigerated
  • With sterile water: Use within 5–7 days
  • Never freeze reconstituted peptides
  • Protect from light

Frequently Asked Questions

CJC-1295 with DAC (Drug Affinity Complex) has a half-life of 5.8–8.1 days due to its ability to bind to albumin, requiring only once or twice weekly injections. CJC-1295 without DAC (Mod GRF 1-29) has a half-life of approximately 30 minutes, requiring multiple daily injections but producing a more natural pulsatile GH release pattern.

Most users report improved sleep within 1–2 weeks. Noticeable changes in body composition, recovery, and muscle fullness typically emerge between weeks 4–8, with peak effects occurring around weeks 8–12 of consistent use.

Many users employ CJC-1295 for its potential anti-aging benefits, as elevated GH and IGF-1 levels are associated with improved skin quality, body composition, and recovery. However, long-term safety data for this application is limited.

Yes. WADA-accredited laboratories can detect CJC-1295 and its metabolites in urine samples. Athletes subject to anti-doping testing should not use this peptide.

For CJC-1295 with DAC, simply resume your regular schedule. Do not double dose. For CJC-1295 without DAC, missing occasional doses is less significant due to the frequent dosing schedule; simply continue with your next planned injection.

Yes. CJC-1295 does not directly affect sex hormones and can be used by women. Dosing is typically similar to that used by men, though some women start at the lower end of the dosing range.

CJC-1295 is most effective when administered on an empty stomach, as elevated blood sugar and insulin can blunt GH release. Most users inject at least 30 minutes before eating or 2–3 hours after a meal.

Early indicators include improved sleep quality, more vivid dreams, and enhanced recovery from exercise. Over time, users may notice increased muscle fullness, fat loss, improved skin quality, and better overall energy levels.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
  2. Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005.
  3. Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006.
  4. Ionescu M, Bhopale G. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog. Growth Hormone & IGF Research. 2009.
  5. Thomas A, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2011.
  6. Aidsmap. Lipodystrophy study halted after patient death. 2006.
  7. World Anti-Doping Agency. The 2024 Prohibited List International Standard.
  8. FDA. CJC-1295 - Pharmacy Compounding Advisory Committee Materials. December 2024.
  9. Hone Health. Everything You Need to Know About the FDA Peptide Ban.
  10. Innerbody. CJC-1295 + Ipamorelin: Benefits, Safety & Buying Advice.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”